Status:

COMPLETED

Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients

Lead Sponsor:

AstraZeneca

Conditions:

Mania

Bipolar Disorder

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

This is a randomised, double blind, double dummy, multicentre, parallel-group study to compare the efficacy and safety of quetiapine and lithium used as monotherapy in the treatment of mania in patien...

Eligibility Criteria

Inclusion

  • Written informed consent for study participation, signed by the patient's legal guardian.
  • Both at screening and at randomization (Day 1), had a YMRS total score of at least 20.

Exclusion

  • Known intolerance or lack of response to quetiapine or lithium, as judged by the investigator.
  • Known or suspected hypersensitivity to quetiapine or lithium.

Key Trial Info

Start Date :

August 1 2005

Trial Type :

INTERVENTIONAL

End Date :

June 1 2006

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT00448578

Start Date

August 1 2005

End Date

June 1 2006

Last Update

December 9 2010

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Research Sites

Beijing, China

2

Research Site

Guangzhou, China

3

Research Site

Kunming, China

4

Research Site

Nanjing, China

Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients | DecenTrialz